Summary of WuXi AppTec Conference Call Company Overview - **Company**: WuXi AppTec (603259.SS) - **Industry**: Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) Key Financial Highlights - **FY25 Revenue**: Estimated at Rmb45.5 billion, representing a **16% year-over-year (yoy)** increase, surpassing management guidance of Rmb43.5-44.0 billion (10-12% yoy) and consensus estimates [1] - **Revenue Growth**: Continued business revenue grew by **21.4% yoy** in 2025, exceeding management's guidance of 17-18% yoy [1] - **FY25 Net Profit**: Estimated at Rmb19.2 billion, a **103% yoy** increase, compared to Rmb16.8 billion (78% yoy) by consensus and Rmb18.5 billion (96% yoy) by Citi estimates [1] - **Adjusted Non-IFRS Net Profit**: Expected to reach Rmb15.0 billion, up **41% yoy**, aligning with higher non-IFRS net margin guidance [1] - **Excluding One-off Items**: FY25 net profit is projected at Rmb13.2 billion, reflecting a **33% yoy** increase, impacted by foreign exchange changes [1] Management Insights - **Gains from Asset Sales**: Management anticipates a net gain of Rmb4.2 billion from the sale of WuXi XDC shares and Rmb1.4 billion from the sale of the clinical business in 2025 [1] Valuation and Target Price - **Target Price**: Rmb130, based on a Net Present Value (NPV) analysis using a Weighted Average Cost of Capital (WACC) of 9.2% and a terminal growth rate of 3% [4] - **Segment Valuation Breakdown**: - WuXi Chemistry: Rmb103.9/share - WuXi Testing: Rmb8.3/share - WuXi Biology: Rmb3.7/share - Investment Income: Rmb5.0/share - Other Services and Net Cash: Rmb9.2/share [4] Risks and Challenges - **Customer Demand**: Potential reduction in customer spending on outsourced services could negatively impact revenue [5] - **Talent Retention**: Challenges in attracting and retaining skilled scientists and technicians may affect operational efficiency [5] - **Regulatory Compliance**: Non-compliance with regulations could harm the company's reputation and financial condition [5] - **Geographic Expansion**: Difficulties in expanding into new markets may limit growth opportunities [5] - **Labor Costs**: Rising labor costs could pressure profit margins [5] - **Geopolitical Risks**: US sanctions and geopolitical tensions may impact business operations [5] Market Position and Competitiveness - **Market Capitalization**: Rmb294.7 billion (approximately US$42.2 billion) [2] - **Expected Total Return**: 34.1%, with an expected dividend yield of 2.3% [2] Conclusion WuXi AppTec is positioned for strong growth in FY25, with significant revenue and profit increases driven by robust demand for its services. However, the company faces several risks that could impact its performance, including regulatory challenges and market competition. The target price reflects a positive outlook based on solid financial fundamentals and growth potential in the CRO/CDMO sector.

Group 1 - The core viewpoint of the article highlights a strong rebound in the pharmaceutical sector in 2025 after four consecutive years of decline, driven by AI and innovative drugs, reflecting a qualitative change in China's innovation capabilities and the realization of overseas expansion logic [1] - The medical device industry experienced a 3.78% decline in December, but is showing signs of recovery due to policy reforms and the resolution of industry governance challenges, with some sub-sectors reaching a fundamental turning point [1] - The CRO/CDMO sector is witnessing a resonance of domestic and international demand, with a recovery in global investment and financing leading to increased orders, alongside a gradual clearing of supply-side issues, which is expected to restore industry profitability [1] Group 2 - The National Medical Products Administration has released the "Priority Approval List for High-end Medical Devices (2025 Edition)," supporting the innovative development of high-end medical devices, indicating potential opportunities for reversing industry challenges [1] - The investment logic for the pharmaceutical sector in 2026 will continue to focus on innovation growth and the reversal of difficulties, with sub-sectors like medical devices expected to maintain a warming trend [1] - The ChiNext Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which has a daily price fluctuation limit of 20%, focusing on innovative pharmaceutical fields and selecting listed companies with high R&D investment and strong innovation capabilities [1]

Core Viewpoint - The article highlights that the recovery of the pharmaceutical industry in China is driven by innovation and policy optimization, with expectations for continued growth in 2026 due to advancements in AI and innovative drugs [1] Group 1: Industry Trends - The pharmaceutical and biotechnology market is expected to be propelled by AI and innovative drugs by 2025, indicating a significant leap in China's innovation capabilities and the potential for international expansion [1] - Despite a temporary pullback in Q4, the industry is gradually recovering after undergoing policy reforms and governance challenges, with a positive outlook for 2026 [1] - The medical device sector is anticipated to experience a fundamental turning point in 2025, with opportunities for recovery in certain sub-sectors, and this trend is expected to continue into 2026 [1] Group 2: Market Dynamics - The CRO/CDMO industry is seeing a resonance of both domestic and international demand, with improvements in demand as global investment and financing recover, while supply is gradually being cleared, leading to a potential rapid recovery in industry profitability [1] - Continuous policy support for innovation is evident, as the National Medical Products Administration has released the "Priority Approval List for High-end Medical Devices (2025 Edition)," which aims to further optimize the review and approval mechanisms to promote innovation in high-end medical devices [1] Group 3: ETF Performance - The Guotai ChiNext Pharmaceutical ETF (159377) has seen an intraday increase of over 1.7%, reflecting the performance of the innovative pharmaceutical sector [1] - This ETF tracks the Innovation Pharmaceutical Index (399275), which focuses on companies with high R&D investment and innovation capabilities across various segments, including biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services [1]

Market Overview - The Hong Kong stock market experienced a downward trend, with the Hang Seng Index closing down 0.94% at 26,458.95 points and a total trading volume of HKD 2,761.34 million [1] - The Hang Seng China Enterprises Index fell by 1.14% to 9,138.75 points, while the Hang Seng Tech Index decreased by 1.49% to 5,738.52 points [1] - Zheshang International noted that the market fundamentals remain weak, with a decline in the funding environment, while policy focus is on new productivity and expanding domestic demand [1] Blue Chip Performance - WuXi Biologics (02269) led blue-chip stocks, rising 5.92% to HKD 36.12, contributing 11.87 points to the Hang Seng Index [2] - Other notable blue-chip performers included Innovent Biologics (01801) up 5.38% and WuXi AppTec (02359) up 4.91%, while Alibaba (09988) fell 3.25%, dragging the index down by 65.17 points [2] Sector Highlights Pharmaceutical Sector - The pharmaceutical sector continued its upward trend, with notable gains from Rongchang Biologics (09995) up 12.93% and Tigermed (03347) up 8.88% [3] - The National Medical Products Administration reported that 76 innovative drugs are expected to be approved by 2025, significantly surpassing the 48 approved in 2024, indicating a strong growth trajectory for the sector [4] Nickel Sector - Nickel stocks showed strong performance, with Xinjiang Xinxin Mining (03833) rising 12.28% and Zhongwei New Materials (02579) up 10% [4] - Nickel prices surged over 20% in the past two weeks, driven by supply constraints from Indonesia, which plans to reduce nickel mining quotas by 2026 [4] Paper Sector - The paper sector saw significant gains, with Nine Dragons Paper (02689) up 8.97% and Lee & Man Paper (02314) up 6.92% [5] - Several paper companies announced price increases, indicating a reduction in production pressure and a more favorable pricing environment [5] Coal Sector - Coal stocks generally rose, with Shougang Resources (00639) up 5.98% and China Qinfa (00866) up 5.92% [6] - The Dalian Commodity Exchange saw a surge in coking coal and coke futures, with expectations of improved supply-demand dynamics in 2026 [6] Optical Communication Sector - Optical communication stocks rebounded, with Yangtze Optical Fibre and Cable (06869) up 6.75% [6] - The sector is expected to benefit from advancements in AI technology and increased demand for high-performance components [7] Notable Stocks - Yadea Group Holdings (01585) announced a profit increase forecast, leading to a 4.63% rise in stock price [8] - JinkoSolar (06680) remained active with a 3.65% increase, driven by potential export restrictions on rare earth materials to Japan [9] - Jitu Express (01519) reached a new high, with a 3.39% increase, reporting significant growth in package volume [10] - GF Securities (01776) faced pressure, declining 4.09% after announcing a share placement and convertible bond issuance to raise funds for international business development [11]

尽管面临持续的地缘政治逆风，药明康德2025年前三季度订单积压同比增长41%，高于全球平均的 14%，凸显其在制药外包市场拥有长期强劲的竞争力。 在估值方面，里昂将药明康德的目标市盈率调整至21倍(原本22倍，以反映1260H清单带来的不确定 性)，高于2022年至2025年的历史平均水平，主要因公司盈利增长恢复至双位数所带来的估值溢价。药 明康德是该行在中国CRO/CDMO行业的首选股。 里昂发布研报称，维持药明康德（603259）(02359)"跑赢大市"评级，目标价上调至143.4港元。里昂预 期，药明康德将受益于外包需求回暖及政策不确定性减弱，预料2026年盈利将明显增长。 报告提及，2026年第一季度有三大催化剂可能推动药明康德股价表现，包括1月12至15日的行业峰会， 将更新CRO行业的最新展望，预计将提振市场信心。其次，1月至2月间公布美国国防部1260H清单，有 望减轻市场对政策的不安情绪。最后，公司在3月的2026全年业绩指引，将进一步确认其盈利增长潜 力。 ...

在估值方面，里昂将药明康德的目标市盈率调整至21倍(原本22倍，以反映1260H清单带来的不确定 性)，高于2022年至2025年的历史平均水平，主要因公司盈利增长恢复至双位数所带来的估值溢价。药 明康德是该行在中国CRO/CDMO行业的首选股。 报告提及，2026年第一季度有三大催化剂可能推动药明康德股价表现，包括1月12至15日的行业峰会， 将更新CRO行业的最新展望，预计将提振市场信心。其次，1月至2月间公布美国国防部1260H清单，有 望减轻市场对政策的不安情绪。最后，公司在3月的2026全年业绩指引，将进一步确认其盈利增长潜 力。 尽管面临持续的地缘政治逆风，药明康德2025年前三季度订单积压同比增长41%，高于全球平均的 14%，凸显其在制药外包市场拥有长期强劲的竞争力。 智通财经APP获悉，里昂发布研报称，维持药明康德(02359)"跑赢大市"评级，目标价上调至143.4港 元。里昂预期，药明康德将受益于外包需求回暖及政策不确定性减弱，预料2026年盈利将明显增长。 ...

Core Viewpoint - The medical ETF (512170) has shown significant performance, with a daily increase of over 5% and reaching a 20-day high, indicating strong market interest and potential growth in the healthcare sector [1]. Group 1: ETF Performance - The medical ETF opened high on January 6 and saw a peak increase of over 1%, with a trading volume exceeding 350 million yuan [1]. - The ETF has recorded five consecutive days of gains, reflecting a robust upward trend in the healthcare sector [1]. Group 2: Component Stocks - Brain-computer interface stocks, specifically Sanbo Brain Science and Meihua Medical, both hit the daily limit up of 20%, marking two consecutive days of gains [1]. - Conversely, the CXO sector experienced a pullback, with Tigermed seeing a decline of over 1% [1]. Group 3: Market Insights - Tesla CEO Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices in 2026, which could accelerate the commercialization of this technology [2]. - The National Medical Products Administration of China held a meeting to expedite the review and approval of related medical devices, indicating regulatory support for the industry [2]. Group 4: Industry Outlook - CITIC Securities highlighted that China's brain-computer interface technology is relatively advanced globally, which may lead to the emergence of leading companies in this field and enhance valuations in the secondary market [3]. - Zhongtai Securities noted a potential rebound in the pharmaceutical sector after four years of decline, driven by the realization of innovative drug export logic and industry recovery due to policy reforms [3].

Group 1 - The medical ETF (512170) opened high on January 6, rising over 1% and reaching a 20-day high, with real-time transaction volume exceeding 350 million yuan. The ETF recorded a daily increase of over 5%, marking five consecutive days of gains [1][5] - Brain-computer interface stocks, including Sanbo Brain Science and Meihua Medical, both hit the 20% daily limit up, achieving two consecutive boards. Conversely, the CXO sector saw a pullback, with Tigermed falling over 1% [1][5] Group 2 - On January 5, 2026, Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices, advancing the commercialization of the technology. Concurrently, the National Medical Products Administration held a meeting to expedite the review and approval of related medical devices [3][6] - According to CITIC Securities, China's brain-computer interface technology is relatively advanced globally, with potential to cultivate leading companies in the sector. This could enhance the valuations of related listed companies in the secondary market and stimulate financing in the primary market, creating a synergy between capital and industry development [7] - Zhongtai Securities noted that the pharmaceutical sector is expected to rebound in 2025 after four consecutive years of decline, driven by the realization of innovative drug export logic and industry recovery post-policy reform. Certain areas of the medical device sector may also see a reversal of difficulties [7]

格隆汇12月24日丨和元生物(688238.SH)在投资者互动平台表示，公司专注于细胞和基因治疗 CRO/CDMO业务，公司持续保持对包括欧盟市场在内的海外业务拓展，目前已有少量CRO服务订单实 现对欧盟国家的出口。 ...

Summary of Key Points from Conference Call Records Industry Overview - The pharmaceutical sector experienced a correction in 2025 but rebounded towards the end of the year, with the innovative drug market expected to continue its momentum into 2026, presenting investment opportunities [1][6][10]. - Current industry hotspots include the flu epidemic, policy support, and breakthroughs in innovative fields such as small nucleic acid drugs, GLP-1, and BCL-2 inhibitors [1][7][8]. Core Insights and Arguments - The overall performance of the pharmaceutical sector in November 2025 was weak, with a decline of 3.6%, underperforming the CSI 300 index by approximately 1.16 percentage points [3]. - The application of AI technology in healthcare, including AI medicine and brain-computer interfaces, is gaining attention and is expected to present opportunities in 2026 [4][12]. - The release of the medical insurance negotiation directory and commercial insurance innovation directory will significantly impact the sales of related products once they enter the insurance system [10]. - Investment recommendations for 2026 include focusing on cutting-edge technologies such as dual antibodies, multi-antibodies, ADC, PROTAC, small nucleic acids, and GLP-1, as well as large companies with strong R&D capabilities and biotech firms with best/first-in-class potential [9][11]. Notable Developments - The flu data has reached new highs, driving up the stock prices of related testing drugs and vaccines [7]. - The third-party laboratory sector is expected to see performance bottoming out in Q4 2025, with a recovery starting in Q1 2026, aided by accelerated payment collection from companies like KingMed and Dian Diagnostics [4][19]. - The PROTAC technology is highlighted for its ability to degrade target proteins, addressing issues of drug resistance, with leading companies like Pfizer, BMS, and BeiGene making significant progress [4][16][17]. Investment Opportunities - Companies such as KingMed and Dian Diagnostics are recommended for investment due to their improving cash flow and potential recovery in the IVD industry [19][20]. - Jichuan Pharmaceutical is included in the December portfolio due to its expected performance rebound driven by flu season demand and low inventory levels [21]. - The CRO industry is poised for growth, with expectations of increased outsourcing rates and improved margins due to a decrease in new entrants [22][23]. Future Trends - The medical device sector is showing positive trends, with expectations for improvement in the consumer healthcare segment in 2026 [2][11]. - The potential for significant growth in the insulin business of companies like Lianbang Pharmaceutical is anticipated, with a projected revenue of 20 billion yuan in 2025 [32][35]. - The upcoming KMR data in December is expected to act as a catalyst for the global PROTAC market, with a focus on companies with substantial technology platforms [18]. Conclusion - The pharmaceutical and healthcare sectors are navigating through a period of adjustment, with various innovative technologies and market dynamics presenting both opportunities and challenges. Investors are advised to keep a close watch on regulatory developments, clinical trial outcomes, and emerging technologies that could shape the future landscape of the industry [1][6][10].